Dog Joint Supplement Survey: Results and Limits
Written by Charlotte Niblett, Copywriter. Reviewed by Dr. Emma Scales-Theobald PhD, Canine Behaviour Expert.
This page preserves the results of a legacy six-week, 22-dog owner survey of a joint tablet that is not currently sold by Finch & Barker in the United States. The findings are historical owner-reported observations, not a randomized blinded clinical trial and not evidence for Finch & Barker Mushroom Chews, Deluxe Pet Dental Spray or every joint supplement. They can be useful when read with their method and limitations.
All participating dogs had owner-reported osteoarthritis. Owners scored quality of life, pain severity and interference with daily activity at enrollment, week three and week six while dogs received the historical joint tablet. There was no placebo group described in the source report.
What the survey did
Owners completed the same questionnaire at three time points. Pain severity and pain interference were scored on a 1-to-10 scale. Quality of life used five categories: poor, fair, good, very good and excellent. Repeating the questions created a consistent timeline, but owners knew their dogs received the product, which can affect reporting.
The sample included 22 dogs from 17 breed types: 16 males and 6 females. The group included small, medium and large dogs. Variety improves relevance, but a small mixed sample cannot establish the effect for every breed, disease severity or medication plan.
Week-three owner reports
| Owner-reported outcome at week three | Dogs or owners reporting improvement |
|---|---|
| Reduction in pain severity | 87% |
| Reduction in how much pain interfered with daily life | 57% |
| Owners reporting less daily-life pain interference | 83% |
| Improvement in quality of life | 63% |
The source uses related but not identical wording for the pain-interference measures, so the figures should not be combined or treated as one endpoint. They describe owner questionnaires, not force-plate testing, veterinary examination or a blinded observer score.
Week-six owner reports
| Owner-reported outcome at week six | Reported figure |
|---|---|
| Dogs with a reduction in pain severity | 68% |
| Reduction in how much pain interfered with daily life | 73% |
| Improvement in quality of life | 64% |
| Owners reporting reduced pain severity | 82% |
| Owners reporting reduced pain interference | 86% |
| Quality of life rated very good or excellent | 72%, compared with 32% at enrollment |
Different rows may describe statistical analyses and owner proportions from the original report. Without a full protocol, raw data and analysis plan, they should be presented as reported rather than recalculated. Improvement over time can reflect treatment, medication, activity, regression to the mean, expectation or the natural course of symptoms.
Quality of life before and after
| Quality-of-life rating | At enrollment | After six weeks |
|---|---|---|
| Poor | 4% | 5% |
| Fair | 23% | 9% |
| Good | 41% | 14% |
| Very good | 27% | 36% |
| Excellent | 5% | 36% |
Very good plus excellent increased from 32% at enrollment to 72% after six weeks. At the same time, the poor category did not disappear. Individual response varied, which is why averages cannot predict one dog's outcome.
Daily activities reported at week six
| Activity | Owners reporting reduced pain interference |
|---|---|
| General activity | 82% |
| Enjoyment of life | 73% |
| Rising to standing from lying down | 59% |
| Walking | 77% |
| Running | 77% |
| Climbing stairs or steps | 73% |
These are practical functions that owners can recognize, but they remain subjective. A stronger future study would pre-register endpoints, standardize concurrent medication and activity, use a randomized control, blind assessors where possible and include veterinary or objective mobility measures.
How to interpret owner testimonials
Owners in the source described easier administration and perceived improvements in enthusiasm, limping and mobility. Testimonials illustrate experience but cannot establish efficacy, frequency or safety. Positive stories are more likely to be shared, and owners know when they start a new product.
Do not use a testimonial to stop prescribed medication, delay surgery or assume a ruptured ligament healed. A dog with lameness needs diagnosis and follow-up.
What the survey can and cannot tell us
It can describe
- How 22 owners scored their dogs across six weeks
- Which functions were included in the questionnaire
- Whether owner ratings moved in a favorable direction
- How acceptable the historical tablet seemed to participating owners
It cannot establish
- That the product caused every change
- How it compares with placebo, medication or another supplement
- The response rate for all dogs with osteoarthritis
- Long-term safety or benefit beyond six weeks
- Results for a different formula or Finch & Barker product
When reviewing a current product with your veterinarian, use our guide to comparing dog joint supplement labels, evidence and quality controls.
How owners can track mobility responsibly
- Get a veterinary diagnosis and baseline.
- Choose two or three repeatable functions.
- Score them at the same time and on the same surface.
- Keep medication and activity stable unless the veterinarian changes them.
- Record side effects, appetite, stool and sleep.
- Set a recheck date and a clear stop rule.
Use short videos from the same angle. A trend across several observations is more useful than one good day. See our arthritis guide and joint-care guide.
Why publishing limitations adds value
Clear limitations protect owners from overinterpreting a promising result. They also show what evidence should come next. Owner-reported outcome measures are important in chronic pain research because home function matters, but they are strongest when paired with a controlled design, validated questionnaire and transparent analysis.
The historical report used the phrase statistically significant, yet the public source did not provide full calculations, confidence intervals, raw data or a registered protocol. This page therefore preserves that statement as reported without independently verifying the statistical analysis.
What a stronger future study would add
A more rigorous trial would define eligibility and osteoarthritis diagnosis in advance, record baseline medication and body condition, randomly assign dogs to groups and use a placebo or active comparator. Owners and outcome assessors would be blinded where practical. The study would specify one primary endpoint before data collection and calculate the sample size needed to detect a meaningful change.
Validated owner questionnaires could be paired with veterinary examination, force-plate gait analysis, activity monitors or standardized walk tests. Adverse events, withdrawals and missing data would be reported for every group. Results would include absolute changes, confidence intervals and the proportion of dogs reaching a pre-defined clinically meaningful improvement.
Longer follow-up matters because osteoarthritis fluctuates and is managed over years. A six-week signal may not persist, and a delayed adverse effect may not appear. Publishing the protocol, funding, formula, daily amount and raw or analyzable data would let readers understand exactly what was tested.
Questions to take to the veterinarian
- Is osteoarthritis the confirmed cause of this dog's signs?
- Which outcome should improve, and by how much?
- What medication, diet or activity must remain stable during a trial?
- Does the exact formula interact with current care?
- What side effect means stop immediately?
- When should videos and scores be reviewed?
- Would a rehabilitation or orthopedic referral add more value?
Bring the exact label and this survey's limitations, not only the headline percentages. A veterinarian can help decide whether the historical formula resembles a current option closely enough to be relevant. Similar marketing categories do not prove equivalent composition.
Why pain measurement is difficult
Dogs cannot describe pain in words, and behavior changes with environment, excitement, weather and the observer. Owners see daily life and are essential reporters, but knowledge of a new product can change expectations. Clinic gait can differ because adrenaline or unfamiliar flooring changes movement.
That is why several measures are stronger than one. A useful assessment combines owner observations, repeated functional tasks, examination and, when available, objective tools. Improvement should be consistent enough to matter to the dog, not only reach a statistical threshold.
Who the survey results may not represent
The source named 17 breed types but did not publish a full breakdown of age, body weight, osteoarthritis severity, affected joints, body condition, medication, diet, activity or other disease. These variables can change pain and function. A group with more mild disease can produce a different response from dogs awaiting orthopedic surgery or managing several chronic conditions.
The survey also relied on owners who volunteered and completed follow-up. Their experiences may differ from owners who stopped early, could not administer the product or did not respond. Without a participant flow diagram and withdrawal reasons, attrition bias cannot be assessed fully.
Owner-reported outcomes still matter
Limitations do not make owner observations worthless. Dogs live at home, and owners see rising, sleep, stairs, play and willingness to walk across many days. A well-designed validated questionnaire can capture changes that a short clinic visit misses. The key is to collect those observations consistently and interpret them alongside other evidence.
For an individual dog, decide in advance what a meaningful change would be. One point on a ten-point scale may matter if the dog now sleeps through the night, but may be noise if the score changes with the observer. Use the same caregiver when possible and document unusual days.
Frequently asked questions
How many dogs were in the survey?
Twenty-two dogs from 17 breed types were described, including 16 males and 6 females.
Was the survey a randomized clinical trial?
No randomized placebo group or blinding was described in the public source. It was an owner-reported six-week product survey.
Did it test a current Finch & Barker product?
No. The historical joint tablet is not currently sold by Finch & Barker in the United States, and results do not transfer to Mushroom Chews or Dental Spray.
Can the results prove pain treatment?
No. Owner reports can describe change but cannot establish causation without stronger controls and supporting clinical evidence.